REMINDER! Live CE Webinar Sponsored by the Division of Drug Information - Drug Information Update

	The Division of Drug Information (DDI) - serving the public by providing information on human drug products and drug product regulation by FDA

FDA’s Division of Drug Information (DDI) is presenting a series of continuing educationwebinars targeting the needs of all health care professionals.

DDI Webinar Series: Tainted Products Marketed as Dietary Supplements 

Will be held on:

November 21, 2017

Time:  1:00 pm to 2:00 pm (EST)

To register for the online meeting, please visit:https://collaboration.fda.gov/ddi111417/event/registration.html

After registering, you will receive a calendar invitation with details on how to join the online meeting.



Activity Outline

Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, students, and other health care professionals, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. The goal of this presentation is to increase awareness of this public health issue, provide an overview of the steps FDA is taking to protect consumers from tainted products, and provide resources about tainted products and the means by which the public can report issues related to these types of products.

Series Objectives:

• Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
• Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.

References:

• Tainted Products Marketed as Dietary Supplements (Database)
• Tainted Products Marketed as Dietary Supplements (Consumer Update)
• Medication Health Fraud
• Letter to Manufacturers of Dietary Supplements
• Some Imported Dietary Supplements and Nonprescription Drug Products May Harm You 

Session Learning Objectives: After completion of this activity, the participant will be able to:

1. Define a “tainted product”
2. Identify the product categories where tainted products are most commonly found
3. Describe one of the regulatory challenges associated with tainted products
4. Identify the resources available on the FDA website about tainted products
5. State how tainted products or adverse events related to tainted products are reported

Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, students, and other health care professionals. 

Schedule:

1:00-2:00 pm – DDI Webinar Series: Tainted Products Marketed as Dietary Supplements presented by Capt. Jason Humbert, MPS, and Nicole Kornspan, MPH

Continuing Education
Accreditation:

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number 0601-0000-17-142-L04-P, and ACPE Universal Activity Number 0601-0000-17-143-L04-T, for 1 contact hour. 

CNE
FDA Center for Drug Evaluation and Research designates this activity for 1 contact hour.

Requirements for receiving CE Credit:
Physicians, physician assistants, nurses, pharmacists, and pharmacy technicians, and those claiming non-physician CME: attendance is verified by Adobe Connect login or by a sign-in sheet, and completion of the final activity evaluation.  Final activity evaluations must be completed within two weeks after the activity. 

Pharmacist and Pharmacy Technician participants: partial credit cannot be awarded; therefore, you must attend the entire activity to receive CPE credit. No exceptions. Pharmacists and Pharmacy Technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit. 

Statements of Credit:
Physicians and Nurses Statements of Credit for CE will be issued 10 weeks after the last session of this activity.  Pharmacists and Pharmacy Technicians should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.  

Disclosure: 
Faculty: 

• Capt. Jason Humbert, MPS, Acting Team Leader, Health Fraud Team, FDA/OGROP/ORA/OEIO/DE/HFB-nothing to disclose
• Nicole Kornspan, MPH, Consumer Safety Officer, Health Fraud Team, FDA/OGROP/ORA/OEIO/DE/HFB-nothing to disclose

Planning Committee:

• Kara Burke, PharmD, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
• Kimberly DeFronzo, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
• Virginia Giroux, MSN, ARNP, CE Program Administrator, FDA/CDER/OEP/DLOD - nothing to disclose
• Danielle Molnar, PharmD, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
• Lesley Navin, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
• Edward Weinstein, MD, Medical Officer, FDA/CDER/OND/OAP/DAIP - discloses the following: “spouse receives salary from EndoCentre of Baltimore as an employee”

CE Consultation and Accreditation Team:

• Justin Gorinson, CHES, ORISE Fellow, FDA/CDER/OEP/DLOD - nothing to disclose
• Karen Zawalick, CE Consultation and Accreditation Team Leader, FDA/CDER/DLOD - nothing to disclose

Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.

Requirements for Certificate of Completion (Non-CE):
Must attend 80% of the lectures (verified by a sign-in sheet). 
--------------
Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov.

FUTURE WEBINAR DATES:
December 5, 2017- DDI Webinar Series: Biosimilars